CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2019 Earnings Presentation
14 slides from CelLBxHealth's earnings presentation, Jan 31, 2019
Slide 1: Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2018
Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2018 Andrew Newland and Ian Griffiths 31 January 2019 © ANGLE plc 2019 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Investment Highlights
Investment Highlights Strengthening a leading position in emerging $ multi-billion liquid biopsy market ANGLE’s ParsortixTM system is a simple blood test for Large scale clinical studies in ovarian cancer personalised cancer care, which harvests viable significantly out-performed existing standard o
Slide 4: Continued strong progress during half year
Continued strong progress during half year FDA analytical and clinical studies nearing completion HyCEAD Ziplex platform further developed delivering outstanding sensitivity for multi gene panel downstream analysis Ovarian cancer test combining Parsortix and HyCEAD Ziplex systems successfully develo
Slide 5: Regulatory clearance for clinical use
Regulatory clearance for clinical use Breast cancer FDA clearance progress 400 subject study Analytical studies progressing well − precision and reproducibility − limits of quantification and detection − accuracy and linearity − interferents and carryover FDA clinical study in progress − 200 metasta
Slide 6: HyCEAD Ziplex high performance multiplex downstream analysis solution
HyCEAD Ziplex® high performance multiplex downstream analysis solution Downstream analysis platform HyCEAD Ziplex − acquired November 2017 providing multiplex cancer gene expression − Analysis of >100 genes in a single reaction − similar to targeted NGS at price of PCR Completed extensive improvemen
Slide 7: Ovarian cancer pelvic mass triage test
Clinical application Ovarian cancer pelvic mass triage test US $1 billion p.a. market potential 400 patient clinical studies demonstrate potential to significantly out-perform current clinical care in discriminating malignant from benign with HyCEAD Ziplex study demonstrating ROC-AUC 95.1% Extensive
Slide 8: Leveraged partnership strategy
Leveraged partnership strategy Abbott: breast cancer HER-2 − process for using Abbott HER-2 FISH test with Parsortix harvested CTCs developed and deployed in FDA clinical study − discussions with Abbott being progressed regarding sales and distribution of the test QIAGEN: prostate cancer AR-V7 − joi
Slide 9: Research use drives growing body of evidence and delivers breakthrough research
Research use drives growing body of evidence and delivers breakthrough research Growing user base (in-house, KOLs, customers and evaluations) − over 60,000 blood separations performed with c. 200 Parsortix instruments in active use − 16 peer-reviewed publications and numerous posters from 19 cancer
Slide 10: Financial Highlights for the six months ended 31 October 2018
Financial Highlights for the six months ended 31 October 2018 Six months ended 31 October 2018 2017 Statement of Comprehensive Income £’000 £’000 Comments Revenue and grant income 370 188 Revenue and grant income up 97% Cost of sales (69) (54) c. 200 Parsortix instruments in active use >60,000 blood
Slide 11: Team strengthened with new appointments
Team strengthened with new appointments Board appointment: Non-executive director Dr Jan Groen CEO MDxHealth, a genomic diagnostics company in prostate and bladder cancers. Previously President Agendia, co-founder of ViroClinics and DxOrange. Management positions at Focus Diagnostics, a subsidiary o
Slide 12: Key next steps
Key next steps Clinical and analytical studies to support first ever FDA clearance to harvest cancer cells from patient blood for subsequent analysis expected to complete in Q1 CY19 Prospect of FDA clearance in CY 2019 Ovarian cancer clinical verification study due to start in Q1 CY19 utilising samp
Slide 13: Investment Highlights
Investment Highlights Strengthening a leading position in emerging $ multi-billion liquid biopsy market ANGLE’s ParsortixTM system is a simple blood test for Large scale clinical studies in ovarian cancer personalised cancer care, which harvests viable significantly out-performed existing standard o
Slide 14: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc ANGLE Biosciences Inc 10 Nugent Road 1150 First Avenue, Suite 1010 50 Ronson Drive, Suite 105 The Surrey Research Park Parkview Tower Toronto Guildford GU2 7AF King of Prussia PA 19406 Ontario M9W 1B3 United Kingdom USA Canada www.ANGLEplc.com © ANG